NYSE:LH - Laboratory Corp. of America Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$137.70 +2.44 (+1.80 %)
(As of 01/21/2019 03:05 AM ET)
Previous Close$137.70
Today's Range$136.08 - $137.82
52-Week Range$119.38 - $190.35
Volume1.18 million shs
Average Volume935,993 shs
Market Capitalization$13.89 billion
P/E Ratio14.34
Dividend YieldN/A
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens. The company also provides specialty testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular disease, infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, medical drug monitoring, and pain management; and esoteric testing, cancer diagnostics, and other complex procedures. In addition, it provides drug development solutions and laboratory testing services; and testing services through a sales force to the managed care organizations, biopharmaceutical companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, food and nutritional companies, and independent clinical laboratories. The company has collaboration with university, hospital and academic institutions, such as Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, and Yale University to license and commercialize new diagnostic tests, as well as with Baptist Health. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

Receive LH News and Ratings via Email

Sign-up to receive the latest news and ratings for LH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services



Sales & Book Value

Annual Sales$10.44 billion
Cash Flow$15.0328 per share
Book Value$67.09 per share


Net Income$1.27 billion


Market Cap$13.89 billion

Laboratory Corp. of America (NYSE:LH) Frequently Asked Questions

What is Laboratory Corp. of America's stock symbol?

Laboratory Corp. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

How were Laboratory Corp. of America's earnings last quarter?

Laboratory Corp. of America Holdings (NYSE:LH) announced its quarterly earnings results on Wednesday, October, 24th. The medical research company reported $2.74 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $2.88 by $0.14. The medical research company earned $2.83 billion during the quarter, compared to the consensus estimate of $2.84 billion. Laboratory Corp. of America had a net margin of 13.27% and a return on equity of 17.13%. The firm's revenue for the quarter was up 8.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.46 earnings per share. View Laboratory Corp. of America's Earnings History.

When is Laboratory Corp. of America's next earnings date?

Laboratory Corp. of America is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Laboratory Corp. of America.

How can I listen to Laboratory Corp. of America's earnings call?

Laboratory Corp. of America will be holding an earnings conference call on Thursday, February 7th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8446341444.

What guidance has Laboratory Corp. of America issued on next quarter's earnings?

Laboratory Corp. of America updated its FY18 earnings guidance on Wednesday, October, 24th. The company provided earnings per share (EPS) guidance of $11.25-11.45 for the period, compared to the Thomson Reuters consensus estimate of $11.53. The company issued revenue guidance of $11.34-11.44 billion, compared to the consensus revenue estimate of $11.43 billion.Laboratory Corp. of America also updated its FY 2018 guidance to $11.25-11.45 EPS.

What price target have analysts set for LH?

17 brokerages have issued 12 month price objectives for Laboratory Corp. of America's stock. Their predictions range from $155.00 to $202.00. On average, they anticipate Laboratory Corp. of America's share price to reach $177.6667 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price. View Analyst Price Targets for Laboratory Corp. of America.

What is the consensus analysts' recommendation for Laboratory Corp. of America?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Corp. of America in the last year. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Laboratory Corp. of America.

What are Wall Street analysts saying about Laboratory Corp. of America stock?

Here are some recent quotes from research analysts about Laboratory Corp. of America stock:
  • 1. According to Zacks Investment Research, "Acquisitions and organic volume expansion positively contributed to LabCorp Diagnostics business in the last-reported quarter. This apart, Covance Drug Development has reported sturdy growth. This uptrend was primarily owing to strategic acquisitions and robust organic growth. On the negative side, following a dismal third quarter show, shares of LabCorp have once again started to slid on account of the company's 2018 guidance cut, announced on November 30.  According to LabCorp, lower-than-expected volume growth within LabCorp Diagnostics, which is also expected to persist for the remainder of the year, compelled the company to lower its full-year guidance. Reflective of these, LabCorp has underperformed its industry in the past three months." (1/17/2019)
  • 2. Canaccord Genuity analysts commented, "We lower our estimates and PT from $162 to $155, which now uses a 13.8x multiple on our lower ’19 Adj. EPS of $11.30." (12/2/2018)

Has Laboratory Corp. of America been receiving favorable news coverage?

Media stories about LH stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Laboratory Corp. of America earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.

Who are some of Laboratory Corp. of America's key competitors?

Who are Laboratory Corp. of America's key executives?

Laboratory Corp. of America's management team includes the folowing people:
  • Mr. David P. King, Chairman, CEO & Pres (Age 62)
  • Mr. Glenn A. Eisenberg, CFO & Exec. VP (Age 57)
  • Mr. F. Samuel Eberts III, Chief Legal Officer, Chief Compliance Officer, Sr. VP & Sec. (Age 58)
  • Mr. John D. Ratliff, Chief Exec. Officer of Covance Drug Devel. (Age 58)
  • Mr. Gary M. Huff, Chief Exec. Officer of Labcorp Diagnostics (Age 51)

Who are Laboratory Corp. of America's major shareholders?

Laboratory Corp. of America's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Pwmco LLC (0.21%), State of Alaska Department of Revenue (0.09%), Nisa Investment Advisors LLC (0.05%), Retirement Systems of Alabama (0.05%), Contravisory Investment Management Inc. (0.03%) and Cardinal Capital Management (0.03%). Company insiders that own Laboratory Corp. of America stock include Adam H Schechter, David P King, Dwight Gary Gilliland, Edward T Dodson, F Samuel Eberts III, Glenn A Eisenberg, Jean-Luc Belingard, Kerrii B Anderson, Lance Berberian, Lisa J Uthgenannt, M Huff Gary, R Sanders Williams and Robert E Mittelstaedt Jr. View Institutional Ownership Trends for Laboratory Corp. of America.

Which institutional investors are selling Laboratory Corp. of America stock?

LH stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Denali Advisors LLC, Gulf International Bank UK Ltd, American National Bank, Sheets Smith Wealth Management, Nisa Investment Advisors LLC, First Hawaiian Bank and JLB & Associates Inc.. Company insiders that have sold Laboratory Corp. of America company stock in the last year include Adam H Schechter, David P King, Edward T Dodson, Glenn A Eisenberg, Kerrii B Anderson, Lisa J Uthgenannt, M Huff Gary and R Sanders Williams. View Insider Buying and Selling for Laboratory Corp. of America.

Which institutional investors are buying Laboratory Corp. of America stock?

LH stock was purchased by a variety of institutional investors in the last quarter, including Pwmco LLC, Pensionfund DSM Netherlands, Pensionfund Sabic, State of Alaska Department of Revenue, BTIM Corp., QUANTRES ASSET MANAGEMENT Ltd, Private Trust Co. NA and Fox Run Management L.L.C.. View Insider Buying and Selling for Laboratory Corp. of America.

How do I buy shares of Laboratory Corp. of America?

Shares of LH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Laboratory Corp. of America's stock price today?

One share of LH stock can currently be purchased for approximately $137.70.

How big of a company is Laboratory Corp. of America?

Laboratory Corp. of America has a market capitalization of $13.89 billion and generates $10.44 billion in revenue each year. The medical research company earns $1.27 billion in net income (profit) each year or $9.60 on an earnings per share basis. Laboratory Corp. of America employs 60,000 workers across the globe.

What is Laboratory Corp. of America's official website?

The official website for Laboratory Corp. of America is http://www.labcorp.com.

How can I contact Laboratory Corp. of America?

Laboratory Corp. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The medical research company can be reached via phone at 336-229-1127 or via email at [email protected]

MarketBeat Community Rating for Laboratory Corp. of America (NYSE LH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  438 (Vote Outperform)
Underperform Votes:  470 (Vote Underperform)
Total Votes:  908
MarketBeat's community ratings are surveys of what our community members think about Laboratory Corp. of America and other stocks. Vote "Outperform" if you believe LH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel